histamine has been researched along with Narcolepsy in 26 studies
Narcolepsy: A condition characterized by recurrent episodes of daytime somnolence and lapses in consciousness (microsomnias) that may be associated with automatic behaviors and AMNESIA. CATAPLEXY; SLEEP PARALYSIS, and hypnagogic HALLUCINATIONS frequently accompany narcolepsy. The pathophysiology of this disorder includes sleep-onset rapid eye movement (REM) sleep, which normally follows stage III or IV sleep. (From Neurology 1998 Feb;50(2 Suppl 1):S2-S7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1)." | 8.12 | Histamine in murine narcolepsy: What do genetic and immune models tell us? ( Dauvilliers, Y; Liblau, R; Melzi, S; Morel, AL; Peyron, C; Scoté-Blachon, C, 2022) |
| "To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease." | 7.79 | Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013) |
| "We counted the number of hypothalamic neurons producing orexin, melanin-concentrating hormone, and histamine in 7 narcolepsy patients and 12 control subjects using stereological techniques." | 7.79 | Increase of histaminergic tuberomammillary neurons in narcolepsy. ( Baumann, CR; Gavrilov, YV; Haybaeck, J; Mignot, E; Reddy, H; Scammell, TE; Valko, PO; Yamamoto, M, 2013) |
| "To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1." | 7.75 | Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009) |
| "To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency." | 7.75 | CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009) |
| "Single doses of SUVN-G3031 up to 20 mg and multiple doses up to 6 mg once daily were found to be safe and well tolerated in healthy young adults." | 6.94 | Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. ( Bhyrapuneni, G; Goyal, VK; Jetta, S; Mohammed, AR; Muddana, NR; Mudigonda, K; Nirogi, R; Palacharla, VRC; Pandey, SK; Ravula, J; Shinde, A, 2020) |
| "Narcolepsy is a sleep disorder characterized in humans by excessive daytime sleepiness and cataplexy." | 5.51 | Impaired histaminergic neurotransmission in children with narcolepsy type 1. ( Dauvilliers, Y; Franco, P; Guyon, A; Inocente, CO; Lin, JS; Plancoulaine, S; Raverot, V; Villanueva, C, 2019) |
| "In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss." | 5.46 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017) |
| "Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice." | 5.42 | Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015) |
| "L-Histidine was administered to three patients with intractable narcolepsy (20 g/day for 2 weeks), to 4 normal volunteers (32." | 5.04 | L-Histidine: failure to affect the sleep-waking cycle in man. ( Fram, DH; Gillin, JC; Henkin, RI; Snyder, F; Wyatt, RJ, 1975) |
| "An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1)." | 4.12 | Histamine in murine narcolepsy: What do genetic and immune models tell us? ( Dauvilliers, Y; Liblau, R; Melzi, S; Morel, AL; Peyron, C; Scoté-Blachon, C, 2022) |
| "To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease." | 3.79 | Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013) |
| "We counted the number of hypothalamic neurons producing orexin, melanin-concentrating hormone, and histamine in 7 narcolepsy patients and 12 control subjects using stereological techniques." | 3.79 | Increase of histaminergic tuberomammillary neurons in narcolepsy. ( Baumann, CR; Gavrilov, YV; Haybaeck, J; Mignot, E; Reddy, H; Scammell, TE; Valko, PO; Yamamoto, M, 2013) |
| "CSF histamine and tele-methylhistamine did not significantly differ between patients with narcolepsy-cataplexy and other etiologies of non-hypocretin-1 deficient central hypersomnias; these measurements, therefore, are not useful in assessing the etiology or severity of centrally mediated hypersomnia." | 3.78 | Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions. ( Bayard, S; Croyal, M; Dauvilliers, Y; Delallée, N; Jaussent, I; Robert, P; Scholz, S; Schwartz, JC, 2012) |
| "To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1." | 3.75 | Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009) |
| "To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency." | 3.75 | CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009) |
| "Single doses of SUVN-G3031 up to 20 mg and multiple doses up to 6 mg once daily were found to be safe and well tolerated in healthy young adults." | 2.94 | Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. ( Bhyrapuneni, G; Goyal, VK; Jetta, S; Mohammed, AR; Muddana, NR; Mudigonda, K; Nirogi, R; Palacharla, VRC; Pandey, SK; Ravula, J; Shinde, A, 2020) |
| "Histamine was first identified in the brain about 50 years ago, but only in the last few years have researchers gained an understanding of how it regulates sleep/wake behavior." | 2.61 | Histamine: neural circuits and new medications. ( Dauvilliers, Y; Franks, NP; Jackson, AC; Scammell, TE; Wisden, W, 2019) |
| "Narcolepsy is a sleep disorder characterized in humans by excessive daytime sleepiness and cataplexy." | 1.51 | Impaired histaminergic neurotransmission in children with narcolepsy type 1. ( Dauvilliers, Y; Franco, P; Guyon, A; Inocente, CO; Lin, JS; Plancoulaine, S; Raverot, V; Villanueva, C, 2019) |
| "In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss." | 1.46 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017) |
| "Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice." | 1.42 | Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 6 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, Y | 1 |
| Takahata, K | 1 |
| Shimazaki, T | 1 |
| Kitamura, S | 1 |
| Seki, C | 1 |
| Ikoma, Y | 1 |
| Ichise, M | 1 |
| Kawamura, K | 1 |
| Yamada, M | 1 |
| Zhang, MR | 1 |
| Higuchi, M | 1 |
| Nishino, I | 1 |
| Suhara, T | 1 |
| Melzi, S | 1 |
| Morel, AL | 1 |
| Scoté-Blachon, C | 1 |
| Liblau, R | 1 |
| Dauvilliers, Y | 8 |
| Peyron, C | 1 |
| Shan, L | 2 |
| Linssen, S | 1 |
| Harteman, Z | 1 |
| den Dekker, F | 1 |
| Shuker, L | 1 |
| Balesar, R | 1 |
| Breesuwsma, N | 1 |
| Anink, J | 1 |
| Zhou, J | 1 |
| Lammers, GJ | 1 |
| Swaab, DF | 1 |
| Fronczek, R | 1 |
| Nirogi, R | 3 |
| Mudigonda, K | 1 |
| Bhyrapuneni, G | 3 |
| Muddana, NR | 3 |
| Shinde, A | 2 |
| Goyal, VK | 1 |
| Pandey, SK | 1 |
| Mohammed, AR | 2 |
| Ravula, J | 1 |
| Jetta, S | 1 |
| Palacharla, VRC | 2 |
| Manoharan, A | 1 |
| Shinde, AK | 1 |
| Padala, NP | 1 |
| Ajjala, DR | 1 |
| Subramanian, R | 2 |
| Benade, V | 1 |
| Daripelli, S | 1 |
| Kamuju, V | 1 |
| Mekala, VR | 1 |
| Petlu, S | 1 |
| Jayarajan, P | 1 |
| Badange, R | 1 |
| Jasti, V | 1 |
| Lopez, R | 1 |
| Barateau, L | 1 |
| Evangelista, E | 1 |
| Chenini, S | 1 |
| Robert, P | 4 |
| Jaussent, I | 2 |
| Franco, P | 1 |
| Inocente, CO | 1 |
| Guyon, A | 1 |
| Villanueva, C | 1 |
| Raverot, V | 1 |
| Plancoulaine, S | 1 |
| Lin, JS | 2 |
| Scammell, TE | 3 |
| Jackson, AC | 1 |
| Franks, NP | 1 |
| Wisden, W | 1 |
| John, J | 1 |
| Thannickal, TC | 1 |
| McGregor, R | 1 |
| Ramanathan, L | 1 |
| Ohtsu, H | 2 |
| Nishino, S | 4 |
| Sakai, N | 1 |
| Yamanaka, A | 1 |
| Stone, C | 1 |
| Cornford, M | 1 |
| Siegel, JM | 2 |
| Valko, PO | 1 |
| Gavrilov, YV | 1 |
| Yamamoto, M | 1 |
| Reddy, H | 1 |
| Haybaeck, J | 1 |
| Mignot, E | 3 |
| Baumann, CR | 2 |
| Saper, CB | 1 |
| Sundvik, M | 1 |
| Panula, P | 1 |
| Bastianini, S | 1 |
| Silvani, A | 1 |
| Berteotti, C | 1 |
| Lo Martire, V | 1 |
| Cohen, G | 1 |
| Zoccoli, G | 1 |
| Mochizuki, T | 1 |
| Sakurai, E | 2 |
| Nevsimalova, S | 1 |
| Yoshida, Y | 1 |
| Watanabe, T | 2 |
| Yanai, K | 2 |
| Kanbayashi, T | 1 |
| Kodama, T | 1 |
| Kondo, H | 1 |
| Satoh, S | 1 |
| Inoue, Y | 1 |
| Chiba, S | 1 |
| Shimizu, T | 1 |
| Bassetti, CL | 1 |
| Croyal, M | 3 |
| Schwartz, JC | 3 |
| Labeeuw, O | 1 |
| Capet, M | 1 |
| Sinton, CM | 2 |
| Delallée, N | 1 |
| Scholz, S | 1 |
| Bayard, S | 1 |
| Willie, JT | 1 |
| Chemelli, RM | 1 |
| Tokita, S | 1 |
| Williams, SC | 1 |
| Kisanuki, YY | 1 |
| Marcus, JN | 1 |
| Lee, C | 1 |
| Elmquist, JK | 1 |
| Kohlmeier, KA | 1 |
| Leonard, CS | 1 |
| Richardson, JA | 1 |
| Hammer, RE | 1 |
| Yanagisawa, M | 1 |
| Fujiki, N | 1 |
| Ripley, B | 1 |
| Kato, M | 1 |
| Bayer, L | 1 |
| Eggermann, E | 1 |
| Serafin, M | 1 |
| Saint-Mleux, B | 1 |
| Machard, D | 1 |
| Jones, B | 1 |
| Mühlethaler, M | 1 |
| Gillin, JC | 1 |
| Fram, DH | 1 |
| Wyatt, RJ | 1 |
| Henkin, RI | 1 |
| Snyder, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects[NCT04631276] | Phase 1 | 12 participants (Actual) | Interventional | 2014-12-11 | Completed | ||
| A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy[NCT04072380] | Phase 2 | 190 participants (Actual) | Interventional | 2019-09-21 | Completed | ||
| A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects[NCT02342041] | Phase 1 | 64 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study[NCT05443373] | 600 participants (Anticipated) | Observational | 2020-06-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for histamine and Narcolepsy
| Article | Year |
|---|---|
Histamine: neural circuits and new medications.
Topics: Animals; Cataplexy; gamma-Aminobutyric Acid; Histamine; Humans; Hypothalamic Area, Lateral; Narcolep | 2019 |
Interactions of the orexin/hypocretin neurones and the histaminergic system.
Topics: Animals; Brain; Histamine; Humans; Intracellular Signaling Peptides and Proteins; Narcolepsy; Neuron | 2015 |
Interactions of the histamine and hypocretin systems in CNS disorders.
Topics: Alzheimer Disease; Animals; Histamine; Histamine Agonists; Histamine H1 Antagonists; Histamine H3 An | 2015 |
Orexin/hypocretin plays a role in the response to physiological disequilibrium.
Topics: Adaptation, Physiological; Animals; Arousal; Brain; Cataplexy; Dopamine; Energy Metabolism; gamma-Am | 2011 |
2 trials available for histamine and Narcolepsy
20 other studies available for histamine and Narcolepsy
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic assessment of histamine H
Topics: Brain; Histamine; Humans; Ligands; Male; Narcolepsy; Neuroprotective Agents; Niacinamide; Positron-E | 2022 |
Histamine in murine narcolepsy: What do genetic and immune models tell us?
Topics: Animals; Histamine; Histidine Decarboxylase; Humans; Mice; Mixed Function Oxygenases; Narcolepsy; Or | 2022 |
Activated Wake Systems in Narcolepsy Type 1.
Topics: Arginine Vasopressin; Corticotropin-Releasing Hormone; Dopamine; Histamine; Humans; Narcolepsy; Nore | 2023 |
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H
Topics: Animals; Dogs; Drug Interactions; Hepatocytes; Histamine; Humans; Microsomes, Liver; Morpholines; Na | 2020 |
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation.
Topics: Animals; Electroencephalography; Histamine; Histamine Agonists; Humans; Male; Methylhistamines; Mice | 2021 |
Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy.
Topics: Adolescent; Adult; Biomarkers; Cataplexy; Child; Female; Histamine; Histocompatibility Testing; HLA- | 2017 |
Impaired histaminergic neurotransmission in children with narcolepsy type 1.
Topics: Adolescent; Body Mass Index; Child; Child, Preschool; Female; Histamine; Humans; Male; Methylhistami | 2019 |
Greatly increased numbers of histamine cells in human narcolepsy with cataplexy.
Topics: Adult; Aged, 80 and over; Animals; Brain; Cataplexy; Cell Count; Disease Models, Animal; Dogs; Femal | 2013 |
Increase of histaminergic tuberomammillary neurons in narcolepsy.
Topics: Aged; Aged, 80 and over; Animals; Ataxin-3; Cell Count; Disease Models, Animal; Female; Histamine; H | 2013 |
Restoration: potential for compensatory changes in numbers of neurons in adult human brain.
Topics: Adult; Brain; Cell Count; Histamine; Humans; Intracellular Signaling Peptides and Proteins; Narcolep | 2013 |
Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency.
Topics: Animals; Body Weight; Cardiovascular System; Cataplexy; Energy Intake; Female; Gene Knockout Techniq | 2015 |
Is low histamine a fundamental cause of sleepiness in narcolepsy and idiopathic hypersomnia?
Topics: Brain; Cataplexy; Disorders of Excessive Somnolence; Histamine; Humans; Intracellular Signaling Pept | 2009 |
Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
Topics: Adult; Cataplexy; Disorders of Excessive Somnolence; Female; Histamine; Humans; Intracellular Signal | 2009 |
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cataplexy; Central Nervous System Stimulants; | 2009 |
Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin.
Topics: Adult; Aged; Disorders of Excessive Somnolence; Female; Histamine; Humans; Idiopathic Hypersomnia; M | 2010 |
Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calibration; Child; Chromatography, High Pressure Liquid | 2011 |
Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions.
Topics: Adult; Disorders of Excessive Somnolence; Female; Histamine; Humans; Male; Methylhistamines; Middle | 2012 |
Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
Topics: Animals; Arousal; Carrier Proteins; Cells, Cultured; Clomipramine; Disease Models, Animal; Efferent | 2003 |
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Cerebral Cortex; Chromatography, Hi | 2001 |
Orexins (hypocretins) directly excite tuberomammillary neurons.
Topics: Action Potentials; Animals; Biotin; Carrier Proteins; Efferent Pathways; Histamine; Hypothalamic Are | 2001 |